


Advanced Therapeutics within Everyone's Reach

CELLTRION, INC.

SECOND-QUARTER 2023
EARNINGS RELEASE

Aug. 14, 2023



Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only before the external audit is completed.

The audit outcomes may cause some changes in this document.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.



CONTENTS

- I. 2Q23 Financial Results
- II. Business Update
- III. R&D Update

01

2Q23 Financial Results

Biosimilar Sales increased, with OPM improved YoY
driven by supply of new pipelines

[Unit: KRW in Billion]

	2Q23	1Q23	QoQ	2Q22	YoY
Sales	524.0	597.6	-12.3%	596.2	-12.1%
Operating Profit	183.0	182.4	+0.3%	203.5	-10.1%
OP Margin	34.9%	30.5%	+4.4%	34.1%	+0.8%


Sales decreased-12.1% YoY

- Total sales volume declined due to sales decreases in other business areas excluding biosimilar
 - Chemical sales diminished due to the adjustment of the global procurement bidding schedule, while other sales (e.g. F&F service) declined as well
 - Biosimilar, our flagship business, increased by +10.4% YoY, driven by the supply of new follow-up pipelines

OP decreased -10.1% YoY

- OPM improved YoY despite a decrease in total sales
 - Although operating profit decreased as the total sales volume shrunk, OPM improved as the supply of highly profitable new products started
 - Expect to expand future profitability through high-margin products such as 'Yuflyma' and 'Remsima SC'

Existing products remain solid with a growing supply of new pipeline



1. Sales mix percentage of each product is based on sales before price adjustments
2. 'Others' comprise F&F service, price adjustment, realized revenue (3Q22) from the sale of Celltrion USA, etc
3. 1Q22 – 2Q22 sales are based on revised financial statements that reflect the impact of discontinued operations following the sale of CT USA

Balance Sheet_Consolidated

Statement of Financial Position Summary


[Unit: KRW Billion]

	Jun. 2023	Dec. 2022
Total Assets	6,287.9	5,891.7
Current Assets	3,205.9	2,929.8
- Cashable Assets ¹	672.9	594.5
Non-current Assets	3,082.0	2,961.9
Total Liabilities	1,895.1	1,617.4
Current Liabilities	1,590.1	1,294.1
Non-Current Liabilities	305.0	323.3
※ Borrowings (Long and Short Term)	834.5	786.7
Shareholder's Equity	4,392.8	4,274.3
Capital Stock	146.4	140.8
Retained Earnings	3,740.7	3,485.1

Net Debt and Debt-Equity Ratio

■ Net Debt² ○ Debt-Equity Ratio³

[Unit: KRW Billion, %]



1. Cashable Assets = Cash & Cash Equivalent, and Short-term financial instrument

2. Net-debt = Borrowings(long & short term) - Cashable Assets

3. Debt to Equity Ratio = Total Liabilities / Shareholder's Equity

Earnings Summary Consolidated



[Unit: KRW Million]

	Quarterly				
	2Q23	1Q23	2Q22	QoQ	YoY
Sales	523,978	597,564	596,230	-12.3%	-12.1%
COGS	247,808	333,387	295,852	-25.7%	-16.2%
Gross Profit	276,170	264,177	300,378	4.5%	-8.1%
(GP Margin)	52.7%	44.2%	50.4%	8.5%	2.3%
SG&A	93,176	81,742	96,841	14.0%	-3.8%
(R&D Expenses)	39,032	29,926	33,483	30.4%	16.6%
Operating Profit	182,994	182,435	203,537	0.3%	-10.1%
(OP Margin)	34.9%	30.5%	34.1%	4.4%	0.8%
Other Non-operating Profit/Loss	2,680	21,010	25,590	-	-
Financial Income/Loss	4,025	4,844	3,532	-	-
Profit before Income Tax	189,699	208,289	232,659	-8.9%	-18.5%
Net Profit	150,873	167,143	184,025	-9.7%	-18.0%
(NP Margin)	28.8%	28.0%	30.9%	0.8%	-2.1%

Earnings Summary

Non-Consolidated




[Unit: KRW Million]

	Quarterly				
	2Q23	1Q23	2Q22	QoQ	YoY
Sales	422,964	535,580	497,973	-21.0%	-15.1%
COGS	196,613	296,117	253,384	-33.6%	-22.7%
Gross Profit	226,351	239,463	243,589	-5.5%	-7.1%
(GP Margin)	53.5%	44.7%	48.9%	8.8%	4.6%
SG&A	63,397	53,940	58,847	17.5%	7.7%
(R&D Expenses)	37,740	28,493	22,137	32.5%	70.5%
Operating Profit	162,954	185,523	184,742	-12.2%	-11.8%
(OP Margin)	38.5%	34.6%	37.1%	3.9%	1.4%
Other Non-operating Profit/Loss	7,876	22,574	13,588	-	-
Financial Income/Loss	5,318	6,366	5,599	-	-
Profit before Income Tax	176,148	214,463	203,929	-17.9%	-13.6%
Net Profit	139,897	171,893	163,231	-18.6%	-14.3%
(NP Margin)	33.1%	32.1%	32.8%	1.0%	0.3%

02


Business Update

INFLIXIMAB




- REMSIMA IV/SC® (Celltrion)
- REMICADE® (JNJ)
- A Biosimilar
- B Biosimilar

RITUXIMAB



- TRUXIMA® (Celltrion)
- MABTHERA® (Roche)
- A Biosimilar
- B Biosimilar


TRASTUZUMAB



- HERZUMA® (Celltrion)
- HERCEPTIN® (Roche)
- A Biosimilar
- Others


Source: IQVIA, Celltrion Healthcare

INFLIXIMAB




- REMSIMA IV® (Celltrion)
- REMICADE® (JNJ)
- A Biosimilar
- B Biosimilar

RITUXIMAB



- TRUXIMA® (Celltrion)
- RITUXAN® (Roche)
- A Biosimilar
- B Biosimilar


TRASTUZUMAB



- HERZUMA® (Celltrion)
- HERCEPTIN® (Roche)
- A Biosimilar
- Others


Source: Symphony Health, Shinhan Investment

EU5 Market Share(Volume)



- Remsima SC + IV market share displayed a continuous upward trend
- 1Q23 Remsima SC market share: Germany 33%, France 21%

EU Volume Sales Trend



- The fastest growing drug, compared to the recently launched blockbuster new drugs (sales volume basis)

* Source: IQVIA, Celltrion Healthcare



03

R&D Update

R&D Progress

Indication	Pipeline	Global Market Size	R&D Status	
			US	EU
Autoimmune Diseases	Remsima[®] SC	-	BLA Submitted (Dec. 2023)	Approved
	Yuflyma[®] adalimumab	\$34.8bn	Approved	
	CT-P43(biosimilar of STELARA[®])	\$17.7bn	BLA Submitted (Jun. 2023)	MAA Submitted (May 2023)
	CT-P47(biosimilar of ACTEMRA [®])	\$2.8bn	In Clinical Phase III	
AMD ¹⁾	CT-P42(biosimilar of EYLEA[®])	\$9.6bn	BLA Submitted (Jun. 2023)	Preparing MAA
Asthma, CIU ²⁾	CT-P39(biosimilar of XOLAIR[®])	\$3.8bn	Preparing BLA	MAA Submitted (Apr. 2023)
Osteoporosis	CT-P41(biosimilar of PROLIA [®])	\$6.2bn	In Clinical Phase III	
Multiple Sclerosis	CT-P53(biosimilar of OCREVUS [®])	\$6.7bn	In Clinical Phase III	

* Source: IQVIA, Regeneron(Eylea)

2Q23 Key Updates

Regulatory submissions on track for global market entry of new products

- CT-P43 (biosimilar of STELARA[®]):** Regulatory submission completed in US, EU, Korea
 - Plan to enter the market as the first mover with cost competitiveness secured through titer maximization
 - Create synergy by expanding our immunology portfolio with IL inhibitors added to the established TNF-a inhibitors
- CT-P42 (biosimilar of EYLEA[®]):** Regulatory submission completed in US and Korea
 - Secure global competitiveness through efficient clinical trial design and PFS formulation differentiation
 - Aim to be the first-to-market, expanding the portfolio domain to ophthalmology
- CT-P39 (biosimilar of XOLAIR[®]):** Regulatory submission completed in EU and Korea
 - Aim to be the first mover, leveraging competitive advantage in development speed
 - Expand the portfolio, including other therapeutic areas of focus beyond immunology and oncology

¹⁾ AMD: Age-related macular degeneration, ²⁾ CIU: Chronic idiopathic urticaria

Partnership Status

Modalities	Partners	R&D status		
		Focus areas	Status	Partnership/Investment
ADC	IKSUDA THERAPEUTICS	B-cell lymphoma, Brest cancer, etc.	Phase I	Equity invt. (largest shareholder)
	PINOTBIO	Solid tumor	Research	Equity invt. /License-in
Bispecific antibody	abpro	Breast cancer	Research	Equity invt. /License-in
New therapeutic antibody	GENUV	2 types of new therapeutic antibody	Research	Joint development
Microbiome antibody	KOBIO LABS	IBD, Atopic dermatitis	Research	Joint development
	LISCure	Parkinson's disease	Research	Joint development
Oral delivery of antibody	Rani THERAPEUTICS	Adalimumab·Ustekinumab pill	Research	Joint development
Oncolytic virus	GENEMEDICINE	Oncolytic virus platform	Research	Joint development
Biomarker	bas genbio	Discovery and validation of genomic biomarkers via development of AI algorithm	Research	Joint development

2Q23 Key Updates

Continued Collaboration for Expansion of New Drug Portfolio

- Enhancing capabilities in biological big data analytics through joint development of biomarkers with Basgenbio
 - Expand R&D from biopharmaceutical development into Big Data Analytics
 - Develop genomic biomarkers* to utilize in clinical trial design, including target discovery

*Biomarker: a measure that indicates the biological state or condition using protein, DNA, RNA, metabolite, etc.
- Jointly developing an orally-administered adalimumab with Rani Therapeutics
 - Develop a high-concentration oral Adalimumab leveraging RaniPill™, a proprietary platform technology
 - Improve competitiveness through formulation differentiation and the development of oral formulation across all biosimilar lines is under review

Advanced Therapeutics within Everyone's Reach

Thank you